Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 305

Results For "patients"

3863 News Found

Akston Biosciences and Biolexis partner to develop second-gen COVID-19 vaccine
News | March 19, 2022

Akston Biosciences and Biolexis partner to develop second-gen COVID-19 vaccine

Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships


Manipal Hospitals deploys wearable technology to monitor post-surgery care
Hospitals | March 19, 2022

Manipal Hospitals deploys wearable technology to monitor post-surgery care

Manipal Hospitals partners with ConnectedLife, leveraging Fitbit wearable technology, for Continuity of Care Post-High-Risk Surgeries built with Google Cloud


USFDA approves Opdualag to treat metastatic melanoma
Drug Approval | March 19, 2022

USFDA approves Opdualag to treat metastatic melanoma

Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab


Thirty five generic manufacturers sign agreements with MPP for Paxlovid
News | March 18, 2022

Thirty five generic manufacturers sign agreements with MPP for Paxlovid

The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris


AstraZeneca launches global R&D post-doctoral challenge
News | March 18, 2022

AstraZeneca launches global R&D post-doctoral challenge

Successful proposals will secure fully funded postdoctoral research positions


Merck discontinues KEYLYNK-101 trial to treat prostate cancer
Biotech | March 18, 2022

Merck discontinues KEYLYNK-101 trial to treat prostate cancer

At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide


Sanofi moves forward with EUROAPI listing on Euronext Paris
Biotech | March 18, 2022

Sanofi moves forward with EUROAPI listing on Euronext Paris

EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions


USFDA approves Rinvoq for ulcerative colitis
Drug Approval | March 17, 2022

USFDA approves Rinvoq for ulcerative colitis

First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology


Zen hospital opens dedicated cancer facility
Hospitals | March 16, 2022

Zen hospital opens dedicated cancer facility

According to the Indian Council of Medical Research (ICMR), there will be an estimated 12 % rise in cancer cases in India in the next five years


Sanofi announces €300 million collaboration with Blackstone Life Sciences
Biotech | March 16, 2022

Sanofi announces €300 million collaboration with Blackstone Life Sciences

The investment will accelerate the overall Sarclisa development program